

WHAT IS CLAIMED IS:

1. A fusion protein comprising:

a disintegrin binding to integrins $\alpha v\beta 3$ and $\alpha 5\beta 1$ ~~or its integrin binding fragments,~~
 which has an amino acid sequence selected from a group consisting of SEQ ID NO: 12,
 5 ~~SEQ ID NO: 13, and SEQ ID NO: 14~~ wherein the amino acid sequence of the disintegrin
 comprising an amino acid sequence of SEQ ID NO: 2, wherein Xaa is S, K, A, I, L or M at
 location 39; R, K, A, E, or G at location 40; A, K or E at location 41; G, R or A at location
 42; K, T or A at location 43; R or A at location 46; I or R at location 47; P, G or A at
 location 48; G at location 50; M, D or N at location 52; P or L at location 53; P at location
 10 ~~65; R, G, P, Y, E or D at location 66; Y, N, W or L at location 67 and H, G, N or Y at~~
~~location 68,~~

other protein binding peptide ~~binding to~~ targeting an angiogenic factor,

the angiogenic factor comprising Angiopoietin (ANG), Ephrin (Eph), Fibroblast
 Growth Factor (FGF), Neuropilin (NRP), Plasminogen Activators, urokinase-type
 15 plasminogen activator receptor (uPAR), Platelet-Derived Growth Factor (PDGF), Placental
 growth factor (PlGF), Tumor Growth Factor beta (TGF- β), Vascular Endothelial Growth
 Factor (VEGF), Vascular Endothelial cadherin (VE-cadherin), Insulin-like Growth Factor
 (IGF), Connective-Tissue Growth Factor (CTGF), Tumor Necrosis Factor alpha (TNF- α),
 Interleukin 1 (IL-1), Interleukin 6 (IL-6), Granulocyte Macrophage Colony-Stimulating
 20 Factor (GM-CSF), and receptors thereof; and

a Fc domain.

2. The fusion protein of claim 1, wherein the other protein binding peptide comprises
 extracellular domains of VEGF receptors.

3. The fusion protein of claim 1, wherein

the Fc domain is a human or humanized constant sub-region comprising an
 immunoglobulin CH2 domain and a CH3 domain; and

the other protein binding peptide having an Ig-like domain D2 of a VEGFR1 and an
 30 Ig-like domain D3 of a VEGFR2.

4. The fusion protein according to claim 1 or 2 comprising the disintegrin, the Fc domain and the other protein binding peptide from C-terminus to N-terminus.
5. The fusion protein according to claim 1 or 2 comprising the disintegrin, the Fc domain and the other protein binding peptide from N-terminus to C-terminus.
6. The fusion protein of any of claims 1-3 further comprising a linker sequence between the disintegrin and the other protein binding peptide.
- 10 7. The fusion protein of any of claims 1-3 further comprising a signal peptide sequence upstream of the other protein binding peptide.
8. The fusion protein according to claim 2, wherein the extracellular domains of VEGF receptors comprise an Ig-like domains D1-D7 of the VEGF receptors.
- 15 9. The fusion protein according to claim 2, wherein extracellular domains of VEGF receptors comprising i) an Ig-like domain D2 of a VEGFR1 and an Ig-like domain D3 of a VEGFR2; or ii) the amino acid sequence of SED ID NO: 10.
- 20 10. The fusion protein of claim 1 or 2 further comprising a GS or G₉ linker between the Fc domain and the disintegrin or the other protein binding peptide.
11. A nucleic acid encoding the fusion protein of any of claims 1-3.
- 25 12. A dimer of the fusion protein of any of claims 1-3.
13. A vector comprising a nucleotide sequence encoding the fusion protein of any of claims 1-3.
- 30 14. A method of producing a fusion protein, comprising culturing a host cell comprising a nucleic acid encoding the fusion protein of any of claims 1-3 under a condition that produces the fusion protein, and recovering the fusion protein produced by the host cell.
15. A composition comprising the fusion protein according to any of claims 1-3 and a pharmaceutically acceptable adjuvant, carrier or excipient.
- 35

16. Use of the fusion protein of any one of claims 1-3 in the manufacture of a medicament for treating/preventing an angiogenic disease.

17. The use of claim 16, wherein the angiogenic disease comprises rheumatoid arthritis, inflammatory arthritis, osteoarthritis, ocular and systemic cancer, tumor related metastasis and invasion, ocular disease characterized by neovascularization or ischemia, uveitis, retinitis pigmentosa, age-related macular degeneration (AMD), diabetic retinopathy and diabetic macular edema (DME).

18. The use of claim 17, wherein the ocular disease characterized by neovascularization or ischemia is choroidal neovascularization.

~~19. Use of the fusion protein of any one of claims 1-3 in the manufacture of a medicament for treating/preventing systemic fibrosis diseases.~~

~~20. The use of claim 19, wherein the systemic fibrosis diseases include idiopathic lung fibrosis (IPF), nonalcoholic steatohepatitis (NASH) or liver fibrosis, diabetic nephropathy and/or kidney fibrosis, dermal fibrosis or keloid, cardio-fibrosis, and ischemia induced stroke.~~

~~21.~~ 24. Use of the fusion protein of any one of claims 1-3 in the manufacture of a medicament for wound healing.